Software firm allies with Amersham
Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView
Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView multimodality workstation to provide quantitative and reproducible methods of image analysis. Molecular imaging promises exact and sensitive information, leading to earlier and more accurate diagnoses-but only if the data can be quantified, according to the two companies. Although Mirada has established relationships with hardware manufacturers, this is its first with a company engaged primarily in pharmaceuticals.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
